The risk of dyspnea in patients treated with third-generation P2Y₁₂ inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials.

ABSTRACT: BACKGROUND:Ticagrelor and prasugrel are two third-generation oral P2Y₁₂ inhibitors which are more commonly used in clinical practice. However, dyspnea has been consecutively reported in patients using third-generation oral P2Y₁₂ inhibitors. This study aims to compare the risk of dyspnea in patients treated with third-generation P2Y₁₂ inhibitors compared with clopidogrel. METHODS:We systematically searched the PubMed, Cochrane Central Register of Controlled Trials databases, ClinicalTrials.gov and Web of Science for randomized control trials (RCTs) comparing ticagrelor or prasugrel with clopidogrel until July 2019. The primary outcome was the incidence of dyspnea. The risk ratios (RR) and 95% confidence intervals (CI) were estimated using meta-analysis. RESU

SUBMITTER: Zhang N 

PROVIDER: S-EPMC7079377 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature